Universal Ibogaine Inc. announced that its co-founder, Dr. Alberto Sola, will present at the Global Summit on Psychedelic Assisted Therapies in Toronto from May 27 to 29, 2022. Dr. Sola, an expert in ibogaine detox treatments, will discuss his findings on Ibogaine Hydrochloride and Acute Opioid Detox on May 28 at 4:15 PM EST. The summit is organized by the Mental Health Commission of Canada and will feature policy makers and researchers, including attendees from Health Canada and the FDA. The event is seen as a vital step toward advancing addiction treatment and awareness.
Universal Ibogaine Inc. (OTCQB: IBOGF) has appointed Shayne Nyquvest as a Capital Markets Advisor, a role aimed at enhancing the company's strategic fundraising efforts. With over 40 years in capital markets, Nyquvest's experience includes past positions at Mackie Research Capital and Canaccord Genuity. CEO Nick Karos expressed confidence in Nyquvest's re-engagement, highlighting his significant contributions to early financing and ongoing plans for Health Canada clinical trials on ibogaine for opioid use disorder. Universal Ibogaine envisions revolutionizing addiction treatment with its ibogaine-based protocol.
Universal Ibogaine Inc. has temporarily closed its Kelburn Recovery Centre in Winnipeg, Manitoba due to flooding caused by excessive winter snowfall and subsequent groundwater issues. The company is evaluating options for ongoing patient care and damage remediation under property and business interruption insurance. Remediation efforts are projected to take at least 2 to 3 months. CEO Nick Karos emphasized the importance of continuing care for patients and hopes to limit damage to a portion of the facility.
Universal Ibogaine Inc. announced the approval of its common shares for trading on the Frankfurt Stock Exchange (FSE) under the ticker symbol JC4. This move aims to enhance liquidity and exposure to European markets. The FSE is Germany's largest stock exchange, facilitating cross-border trading. CEO Nick Karos emphasized the listing as pivotal for capital markets strategy, with growing interest in the company's innovative addiction treatment solutions. Universal Ibogaine is working on a clinical trial in Canada to validate its ibogaine-based treatment for opioid use disorder.